Alligator Bioscience Announces First Patient Dosed in OPTIMIZE-1 Phase II Clinical Trial Evaluating Mitazalimab in Combination with mFOLFIRINOX for the Treatment of Pancreatic Cancer
Lund, Sweden, September 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that it has dosed the first patient in it’s OPTIMIZE-1 phase II study, which aims to further assess the efficacy and safety profile of Alligator’s CD40 agonist, Mitazalimab, in combination with standard-of-care chemotherapy, mFOLFIRINOX, for the treatment of first-line metastatic pancreatic cancer. OPTIMIZE-1 is an open-label, multicenter study that will enroll up to 67 patients at clinical sites in Belgium and France. The company is expecting an interim safety readout in Q1 2022 and an